The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

NCT05772520 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: TLL018 tablets

Sponsor

Hangzhou Highlightll Pharmaceutical Co., Ltd